Review of Multimodality Management of Anaplastic Thyroid Cancer

This study has been completed.
Information provided by:
AHS Cancer Control Alberta Identifier:
First received: January 20, 2006
Last updated: November 18, 2011
Last verified: July 2011

To describe the outcome of patients with anaplastic thyroid cancer treated with hyperfractionated radiotherapy and concomitant chemotherapy

Anaplastic Thyroid Cancer

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: A Retrospective Review of Multimodality Management of Anaplastic Thyroid Cancer

Resource links provided by NLM:

Further study details as provided by AHS Cancer Control Alberta:

Enrollment: 5
Study Start Date: January 2006
Study Completion Date: June 2006
Primary Completion Date: June 2006 (Final data collection date for primary outcome measure)

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

anaplastic thyroid cancer


Inclusion Criteria:

  • anaplastic thyroid cancer treated with multimodality treatment

Exclusion Criteria:

  • differentiated thyroid cancer
  Contacts and Locations
Please refer to this study by its identifier: NCT00280852

Canada, Alberta
Tom Baker Cancer Centre
Calgary, Alberta, Canada, T2N 4N2
Sponsors and Collaborators
AHS Cancer Control Alberta
Principal Investigator: Harold Lau, MD Alberta Cancerboard
  More Information

No publications provided Identifier: NCT00280852     History of Changes
Other Study ID Numbers: 18940
Study First Received: January 20, 2006
Last Updated: November 18, 2011
Health Authority: Canada: Health Canada

Keywords provided by AHS Cancer Control Alberta:
anaplastic thyroid cancer

Additional relevant MeSH terms:
Thyroid Neoplasms
Thyroid Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Endocrine System Diseases processed this record on April 16, 2014